CRON vs. TLRY, USNA, CGC, MNMD, BTMD, ACB, CDXC, MDWD, FTLF, and BGXX
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Tilray (TLRY), USANA Health Sciences (USNA), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), ChromaDex (CDXC), MediWound (MDWD), FitLife Brands (FTLF), and Bright Green (BGXX). These companies are all part of the "medicinals & botanicals" industry.
Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability, community ranking and valuation.
Cronos Group currently has a consensus price target of $3.00, indicating a potential upside of 15.83%. Tilray has a consensus price target of $2.71, indicating a potential upside of 50.46%. Given Tilray's stronger consensus rating and higher possible upside, analysts clearly believe Tilray is more favorable than Cronos Group.
In the previous week, Tilray had 4 more articles in the media than Cronos Group. MarketBeat recorded 11 mentions for Tilray and 7 mentions for Cronos Group. Cronos Group's average media sentiment score of 0.38 beat Tilray's score of 0.37 indicating that Cronos Group is being referred to more favorably in the media.
Cronos Group has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Tilray has a beta of 2.36, indicating that its stock price is 136% more volatile than the S&P 500.
Cronos Group has higher earnings, but lower revenue than Tilray. Cronos Group is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks.
Tilray has a net margin of -43.98% compared to Cronos Group's net margin of -61.31%. Tilray's return on equity of -2.68% beat Cronos Group's return on equity.
8.7% of Cronos Group shares are owned by institutional investors. Comparatively, 9.4% of Tilray shares are owned by institutional investors. 6.9% of Cronos Group shares are owned by insiders. Comparatively, 0.7% of Tilray shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Cronos Group received 17 more outperform votes than Tilray when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.28% of users gave Tilray an outperform vote.
Summary
Tilray beats Cronos Group on 11 of the 18 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
